On ECHEMI
Home > Drugs > Compound Electrolyte Glucose Injection-M3B

Compound Electrolyte Glucose Injection-M3B

Function and Efficacy

In rabbits within 4 days of surgical invasion, the electrolytes (Na, K, C1) were maintained in a good balance from the first to the fourth day after surgery by intravenous drip of 50ml/kg/day. In addition, blood pH, PC02, and H2CO3 also returned to preoperative values on the fifth day after surgery, and plasma non-protein nitrogen (NPN) concentration also dropped to preoperative values on the third day after surgery, so it is an effective postoperative maintenance fluid.

Ingredients

This product is a compound preparation, and its composition is: each 500ml bottle contains 0.875g sodium chloride, 0.75g potassium chloride, 1.12g sodium lactate, and 13.50g glucose.

Name Description Content CAS NO. Manufacturer
Sodium chlorideIngredients

Maintain electrolyte balance, regulate blood pH and postoperative recovery

More
7647-14-5 43
Potassium chlorideIngredients

Maintain electrolyte balance, regulate blood pH and postoperative recovery

More
7447-40-7 38
Sodium lactateIngredients

Maintain electrolyte balance, regulate blood pH and postoperative recovery

More
312-85-6 0
GLUCOSEIngredients

Maintain electrolyte balance, regulate blood pH and postoperative recovery

More
58367-01-4 14

Appearance

This product is a colorless or almost colorless clear liquid.

Indication

Fluid and electrolyte replenisher. Replenishes and maintains fluids and electrolytes when oral intake is impossible or insufficient.

Usage and Dosage

For adults, 500ml~1000ml intravenous drip at a time. The administration rate is 300ml~500ml per hour (about 80~130 drops per minute); for children, 50ml~100ml per hour, and the dosage can be increased or decreased appropriately according to age, symptoms and weight.

Adverse Reactions

When large amounts of the drug are administered rapidly, pulmonary edema, cerebral edema, peripheral edema, water intoxication, and hyperkalemia may occur.

Precautions

1. Hyperlactatemia; 2. Patients with hyperkalemia, oliguria, Addison's disease, severe burns, and hyperazotemia; 3. Patients with renal insufficiency without hyperkalemia; 4. Patients with heart failure; 5. Patients with severe liver failure; 6. Patients with decreased urine volume due to obstructive urinary tract disease; 7. Patients with diabetes.

Drug Interactions

Not yet clear.

Storage

Keep tightly closed.

Packaging Specification

500ml

Manufacturer

Guangdong Otsuka Pharmaceutical Co., Ltd.

  • Founded in:

    1993-06-01
  • Address:

    Foshan Shunde District Ronggui Street High-tech Industrial Development Park
  • Tax NO.:

    91440606617475057M
  • Registered Funds:

    $28.4 million
  • Website:

  • Email:

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.